A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

• Status: Completed
• Trial end date: 2008-02-01

Summary

The purpose of this study is to evaluate the safety and efficacy of ABT-335 and rosuvastatin calcium combination therapy to monotherapy in subjects with dyslipidemia.

• Phase: Phase 3

Details

• Lead Sponsor: AstraZeneca
• Treatments: Calcium; Calcium, Dietary; Fenofibric acid; Rosuvastatin Calcium